文献速递免疫规划传染病防控与疫情报告

CD4+与CD8+ T细胞多表位嵌合蛋白联合MPLA佐剂诱导保护效力及长期免疫记忆用于美洲皮肤利什曼病免疫预防

CD4+ and CD8+ T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis.
PubMed 文献 · Vaccine · 2024-08-02

本研究基于亚马逊利什曼原虫和巴西利什曼原虫免疫蛋白质组中CD4+/CD8+ T细胞多表位设计嵌合蛋白rChiP,在小鼠感染模型中测试rChiP及rChiP+MPLA-PHAD®配方;两配方均减少皮肤病变发展和寄生虫负荷,并诱导CD4+/CD8+ T细胞产生一氧化氮、促炎细胞因子及中央和效应记忆T细胞,作者认为该配方可作为预防美洲皮肤利什曼病的潜在工具。

要点

  • rChiP由亚马逊利什曼原虫和巴西利什曼原虫免疫蛋白质组中CD4+/CD8+ T细胞多表位融合设计。
  • rChiP和rChiP+MPLA配方均减少小鼠皮肤病变发展和寄生虫负荷。
  • 疫苗组伴随亚硝酸盐、CD4+/CD8+IFN-γ+TNF-α+及CD44highCD62Lhigh/low T细胞、IgGTotal和IgG2a升高,IgG1和CD4+/CD8+IL-10+降低。

核心结论

  • 作者认为所提出的rChiP和rChiP+MPLA配方可作为预防美洲皮肤利什曼病的潜在工具。

研究设计与样本

  • 研究基于亚马逊利什曼原虫和巴西利什曼原虫免疫蛋白质组中鉴定的CD4+/CD8+ T细胞多表位融合设计嵌合蛋白rChiP。
  • 在亚马逊利什曼原虫小鼠感染模型中测试以下配方:25 μg rChiP溶于生理盐水(rChiP组)和25 μg rChiP加25 μg MPLA-PHAD®(rChiP+MPLA组)。

主要发现

  • 免疫完成后,经SLa-Antigen或rChiP刺激的CD4+和CD8+ T细胞一氧化氮和胞内促炎细胞因子产生增加,并生成中央和效应记忆T细胞。
  • rChiP和rChiP+MPLA配方均促进对亚马逊利什曼原虫感染的有效保护,表现为皮肤病变发展减少和寄生虫负荷降低。
  • 疫苗组皮肤病变发展减少和寄生虫负荷降低与亚硝酸盐、CD4+/CD8+IFN-γ+TNF-α+和CD4+/CD8+CD44highCD62Lhigh/low T细胞、IgGTotal、IgG2a升高以及IgG1和CD4+/CD8+IL-10+降低相关。

关键数值与推荐

  • rChiP组:25 μg rChiP溶于生理盐水;rChiP+MPLA组:25 μg rChiP加25 μg MPLA-PHAD®。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

American Tegumentary Leishmaniasis (ATL) is a disease of high severity and incidence in Brazil, in addition to being a worldwide concern in public health. Leishmania amazonensis is one of the etiological agents of ATL, and the inefficiency of control measures, associated with the high toxicity of the treatment and the lack of effective immunoprophylactic strategies, makes the development of vaccines indispensable and imminent. In this light, the present study proposes to elaborate a chimeric protein (rChiP), based on the fusion of multiple epitopes of CD4+/CD8+ T cells, identified in the immunoproteome of the parasites L. amazonensis and L. braziliensis. The designed chimeric protein was tested in the L. amazonensis murine model of infection using the following formulations: 25 μg of the rChiP in saline (rChiP group) and 25 μg of the rChiP plus 25 μg of MPLA-PHAD® (rChiP+MPLA group). After completing immunization, CD4+ and CD8+ T cells, stimulated with SLa-Antigen or rChiP, showed an increased production of nitric oxide and intracytoplasmic pro-inflammatory cytokines, in addition to the generation of central and effector memory T cells. rChiP and rChiP+MPLA formulations were able to promote an effective protection against L. amazonensis infection determined by a reduction in the development of skin lesions and lower parasitic burden. Reduction in the development of skin lesions and lower parasitic burden in the vaccinated groups were associated with an increase of nitrite, CD4+/CD8+IFN-γ+TNF-α+ and CD4+/CD8+CD44highCD62Lhigh/low T cells, IgGTotal, IgG2a, and lower rates of IgG1 and CD4+/CD8+IL-10+. This data suggests that proposed formulations could be considered potential tools to prevent ATL.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moura DM, Carvalho AMRS, Brito RCF, et al. CD4+ and CD8+ T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis. Vaccine. 2024. PMID: 39096765. doi:10.1016/j.vaccine.2024.126178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。